About Pulse Biosciences, Inc. 
Pulse Biosciences, Inc.
Pharmaceuticals & Biotechnology
Pulse Biosciences, Inc. is a clinical-stage medical device company using a platform technology called Nano-Pulse stimulating (NPS). NPS is a non-thermal, precise, focal drug-free electroceutical treatment technology that initiates cell death within treated tissue. NPS provides treatment in a range of immuno-oncology, dermatology and aesthetic applications. It offers treatment for minimally invasive applications, such as cardiac ablation, lung disease, Barret's esophagus, thyroid nodules, and ear, nose and throat (ENT) papillomas. The Company is developing PulseTx system (PulseTx), a system for the delivery of NPS treatments. The PulseTx system delivers NPS pulses through its tunable pulse generator and its planned suite of electrodes. The PulseTx system pulses are applied directly to tissue through electrodes, creating transient nanometer pores in cell and organelle membranes.
Company Coordinates 
Company Details
3957 Point Eden Way , HAYWARD CA : 94545-3720
Registrar Details
Shareholding Snapshot
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 21 Schemes (4.46%)
Foreign Institutions
Held by 29 Foreign Institutions (0.45%)
Strategic Entities with highest holding
Highest Public shareholder
Management
Designation
Mr. Robert Duggan
Independent Chairman of the Board
Mr. Darrin Uecker
President, Chief Executive Officer, Director
Mr. Kenneth Clark
Independent Director
Mr. Mitchell Levinson
Independent Director
Mr. Manmeet Soni
Independent Director
Dr. Mahkam Zanganeh
Independent Director
Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-19 Million
Pharmaceuticals & Biotechnology
USD 1,012 Million ()
NA (Loss Making)
NA
0.00%
-1.00
-63.29%
9.68






